GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+12.2%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$276M
AUM Growth
+$276M
(-4%)
Cap. Flow
-$42.3M
Cap. Flow
% of AUM
-15.35%
Top 10 Holdings %
Top 10 Hldgs %
40.38%
Holding
70
New
9
Increased
16
Reduced
22
Closed
18
Top Buys
| 1 |
Novo Nordisk
NVO
|
$13.1M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$9.25M |
| 3 |
Sarepta Therapeutics
SRPT
|
$8.12M |
| 4 |
Janux Therapeutics
JANX
|
$6.36M |
| 5 |
Edgewise Therapeutics
EWTX
|
$5.2M |
Top Sells
| 1 |
Biohaven
BHVN
|
$17M |
| 2 |
Viridian Therapeutics
VRDN
|
$11.7M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$8.65M |
| 4 |
Vaxcyte
PCVX
|
$8M |
| 5 |
Soleno Therapeutics
SLNO
|
$7.57M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sarepta Therapeutics
SRPT
$1.78B
| $15M | 4.53% | 120,000 +65,000 | +118% | +$8.12M |
|
|
2
Novo Nordisk
NVO
$251B
| $13.1M | 3.96% | +110,000 | New | +$13.1M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $13M | 3.91% | 140,000 +100,000 | +250% | +$9.25M |
|
4
Axsome Therapeutics
AXSM
$6.05B
| $12.1M | 3.66% | 135,000 -15,000 | -10% | -$1.35M |
|
5
Tarsus Pharmaceuticals
TARS
$2.47B
| $11.5M | 3.48% | 350,000 +115,000 | +49% | +$3.78M |
|
6
Perspective Therapeutics
CATX
$250M
| $10M | 3.02% | 750,000 -175,000 | -19% | -$2.34M |
|
7
CG Oncology
CGON
$2.04B
| $9.43M | 2.85% | 250,000 -10,000 | -4% | -$377K |
|
8
Roivant Sciences
ROIV
$8.15B
| $9.23M | 2.79% | 800,000 -200,000 | -20% | -$2.31M |
|
|
9
Vaxcyte
PCVX
$4B
| $9.14M | 2.76% | 80,000 -70,000 | -47% | -$8M |
|
10
Viking Therapeutics
VKTX
$3.04B
| $8.86M | 2.68% | 140,000 +45,000 | +47% | +$2.85M |
|
11
Syndax Pharmaceuticals
SNDX
$1.41B
| $8.66M | 2.62% | 450,000 +100,000 | +29% | +$1.93M |
|
|
12
Janux Therapeutics
JANX
$1.37B
| $8.63M | 2.61% | 190,000 +140,000 | +280% | +$6.36M |
|
13
Ascendis Pharma
ASND
$11.8B
| $7.84M | 2.37% | 52,500 -34,221 | -39% | -$5.11M |
|
14
Crinetics Pharmaceuticals
CRNX
$2.92B
| $7.67M | 2.32% | 150,000 -90,000 | -38% | -$4.6M |
|
|
15
Soleno Therapeutics
SLNO
$3.6B
| $7.57M | 2.29% | 150,000 -150,000 | -50% | -$7.57M |
|
16
TG Therapeutics
TGTX
$4.65B
| $7.25M | 2.19% | 310,000 -190,000 | -38% | -$4.44M |
|
17
Rezolute
RZLT
$619M
| $7.15M | 2.16% | 1,474,995 +53,494 | +4% | +$259K |
|
18
Phathom Pharmaceuticals
PHAT
$864M
| $6.78M | 2.05% | 375,000 -225,000 | -38% | -$4.07M |
|
|
19
MoonLake Immunotherapeutics
MLTX
$3.54B
| $6.47M | 1.96% | 128,411 -171,589 | -57% | -$8.65M |
|
20
Olema Pharmaceuticals
OLMA
$375M
| $6.39M | 1.93% | 535,000 -15,000 | -3% | -$179K |
|
21
Immunovant
IMVT
$2.56B
| $6.13M | 1.85% | 215,000 -45,000 | -17% | -$1.28M |
|
22
Insmed
INSM
$28.8B
| $5.48M | 1.65% | 75,000 +10,000 | +15% | +$730K |
|
|
23
Edgewise Therapeutics
EWTX
$1.51B
| $5.2M | 1.57% | +195,000 | New | +$5.2M |
|
24
Replimune Group
REPL
$422M
| $4.93M | 1.49% | 450,000 | – | – |
|
25
BridgeBio Pharma
BBIO
$9.89B
| $4.46M | 1.35% | 175,000 +35,000 | +25% | +$891K |
|